|
Market Closed -
Nasdaq
16:00:00 2026-11-12 EST
|
5-day change | 1st Jan Change | ||
| 102.91 USD | -3.66% |
|
+6.54% | +214.13% |
| 11-05 | Deutsche Bank Adjusts Spyre Therapeutics PT to $123 From $127, Maintains Buy Rating | MT |
| 11-04 | Wedbush Trims Price Target on Spyre Therapeutics to $120 From $123, Keeps Outperform Rating | MT |
Company Valuation: Spyre Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 234.3 | 27.67 | 775.2 | 1,367 | 2,542 | 9,773 | - | - |
| Change | - | -88.19% | 2,701.1% | 76.31% | 85.99% | 284.48% | - | - |
| Enterprise Value (EV) 1 | 234.3 | 27.67 | 435.6 | 763.6 | 1,785 | 8,874 | 8,929 | 9,073 |
| Change | - | -88.19% | 1,473.95% | 75.31% | 133.81% | 397.02% | 0.62% | 1.62% |
| P/E | -4.75x | -0.45x | -0.44x | -7.32x | -16.5x | -32.5x | -26.3x | -22.8x |
| PBR | 2.79x | - | - | - | 2.93x | 7.05x | 11.1x | 18.1x |
| PEG | - | 0.45x | -0x | 0.1x | 0.4x | -0.5x | -1.1x | -1.5x |
| Capitalization / Revenue | 12.5x | 11.9x | 875x | - | - | - | - | - |
| EV / Revenue | 12.5x | 11.9x | 492x | - | - | - | - | - |
| EV / EBITDA | - | - | -1.8x | -3.66x | -8.52x | -29.3x | -21x | -18.6x |
| EV / EBIT | -3.57x | -0.33x | -1.8x | -3.66x | -8.52x | -29.2x | -20.1x | -17.7x |
| EV / FCF | -4.32x | - | -4.36x | -4.85x | -10.5x | -36.3x | -24.4x | -23.2x |
| FCF Yield | -23.2% | - | -22.9% | -20.6% | -9.48% | -2.76% | -4.09% | -4.31% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -25 | -24.75 | -49.12 | -3.18 | -1.98 | -3.166 | -3.919 | -4.505 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.74 | 2.329 | 0.886 | - | - | - | - | - |
| EBITDA 1 | - | - | -241.6 | -208.6 | -209.6 | -303.1 | -424.4 | -489 |
| EBIT 1 | -65.65 | -84.78 | -242.3 | -208.6 | -209.6 | -304 | -443.4 | -511.9 |
| Net income 1 | -65.8 | -83.82 | -338.8 | -208 | -155.2 | -294 | -400.4 | -464 |
| Net Debt 1 | - | - | -339.6 | -603.1 | -756.5 | -899.5 | -844.4 | -700 |
| Reference price 2 | 118.75 | 11.25 | 21.52 | 23.28 | 32.76 | 102.91 | 102.91 | 102.91 |
| Nbr of stocks (in thousands) | 1,973 | 2,460 | 36,021 | 58,706 | 77,592 | 94,969 | - | - |
| Announcement Date | 3/8/22 | 3/2/23 | 2/29/24 | 2/27/25 | 2/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -32.5x | - | -29.27x | -.--% | 9.77B | |
| 17.83x | 6.87x | 13.17x | 1.67% | 68.45B | |
| 33.16x | 8.87x | 29.33x | 0.07% | 61.31B | |
| 38.6x | 6.87x | 20.53x | 0.84% | 55.73B | |
| 44.64x | 6.26x | 29.95x | -.--% | 47.51B | |
| 35.38x | 3.35x | 14.45x | -.--% | 44.68B | |
| -21.05x | 55.83x | -23.07x | -.--% | 38.14B | |
| 35.39x | 8.76x | 22.85x | 0.37% | 35.85B | |
| 41.18x | 8.09x | 26.85x | -.--% | 33.05B | |
| -72.05x | 13.64x | -73.33x | -.--% | 25.9B | |
| Average | 12.06x | 13.17x | 3.15x | 0.3% | 42B | |
| Weighted average by Cap. | 20.81x | 11.95x | 10.83x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SYRE Stock
- Valuation Spyre Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
